498 related articles for article (PubMed ID: 15255796)
1. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
Bonate PL; Floret S; Bentzen C
Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
4. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients.
Perez-Ruixo JJ; Piotrovskij V; Zhang S; Hayes S; De Porre P; Zannikos P
Br J Clin Pharmacol; 2006 Jul; 62(1):81-96. PubMed ID: 16842381
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.
Alberts DS; Hallum AV; Stratton-Custis M; Garcia DJ; Gleason-Guzman M; Salmon SE; Santabarbara P; Niesor EJ; Floret S; Bentzen CL
Clin Cancer Res; 2001 May; 7(5):1246-50. PubMed ID: 11350890
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
[TBL] [Abstract][Full Text] [Related]
13. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
[TBL] [Abstract][Full Text] [Related]
14. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
Stangier J; Rathgen K; Stähle H; Gansser D; Roth W
Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of Theophylline (CAS No. 58-55-9) in F344/N Rats and B6C3F1 Mice (Feed and Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1998 Aug; 473():1-326. PubMed ID: 12571677
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Tortorici MA; Cohen EE; Pithavala YK; Garrett M; Ruiz-Garcia A; Kim S; Fruehauf JP
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers.
Huang J; Zhang Y; Huang X; Li L; Li Y; Wang K; Yang J; He Y; Lv Y; Zheng Q
Int J Clin Pharmacol Ther; 2014 Jan; 52(1):8-14. PubMed ID: 24219967
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
